Short-Term Debt to Equity Ratio: Cara Therapeutics, Inc. (CARA)
This daily price chart for Cara Therapeutics, Inc. (CARA) reflects the asset's dynamics, with its indicator fixed at 0.02. Cara Therapeutics, Inc. (CARA) is developing a comprehensive environment for the therapy of renal pruritus by integrating its treatments into the practice of dialysis clinics. The business relies on the creation of unique selective kappa-receptor agonists, actively investing in the study of small molecules. The stability of its neurology expert staff is guaranteed by robust intellectual property protection.
Metric breakdowns and analytics for caratherapeutics.com (CARA)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Cara Therapeutics, Inc.|CARA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Cara Therapeutics|CARA - Company Aggregate Debts|Debt to Book Capitalization Ratio Cara Therapeutics Inc.|CARA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Cara Therapeutics|Quick Liquidity Indicator caratherapeutics.com
- company profitability and valuation multiples indicators:
Comprehensive company analysis:CARA Cara Therapeutics, Inc
Driven by strong pricing power in licensing its unique peptide, Corsuva, Cara Therapeutics, Inc. (CARA) effectively manages liquidity; consequently, the short-term debt-to-equity ratio, which measures the proportion of liabilities with a term exceeding one year relative to equity, serves as an indicator of debt sustainability, allowing investors to distinguish market noise from actual credit crisis risks through the price action on this chart.
Direct competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio denalitherapeutics.com (DNLI)|Short-Term Debt to Capital HRMY|Short-Term Debt to Capital Biohaven Ltd (BHVN)|Short-Term Debt to Equity Amylyx AMLX|Ratio of Short-Term Indebtedness to Capital TRVI|Praxis Precision Medicines - Short-Term Debt to Capital|AVXL - Short-Term Debt to Capital|CBLL (CeriBell) - Short-Term Debt to Equity Ratio|Prothena Biosciences - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio ALEC|ANNX (Annexon Biosciences Inc.) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital OMER|NGNE (neurogene.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ACIU (AC Immune SA)|Voyager Therapeutics Inc (VYGR) - Current Liabilities to Capital|NMRA - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital SCLX (Scilex Holding Company, Inc.)|TVGN: Short-Term Debt to Capital|Alpha Cognition Inc. (ACOG) - Short-Term Debt to Capital|Short-Term Debt to Equity Cognition Therapeutics, Inc.|Inhibikase Therapeutics Inc - Current Liabilities to Equity|Short-Term Debt to Capital SAVA|ASRT - Current Liabilities to Capital|Coya Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital VistaGen Therapeutics, Inc. VTGN|OVID: Short-Term Debt to Equity Ratio|Acumen Pharmaceuticals Inc. - Short-Term Loans to Capital Ratio|CRVO: Short-Term Debt to Capital|ATHE - Short-Term Debt to Capital Coefficient|CLNN (Clene Inc) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio PepGen Corp (PEPG)|Short-Term Debt to Equity Jupiter Neurosciences (JUNS)|Short-Term Debt to Capital Coefficient Relmada Therapeutics Inc|Annovis Bio Corp - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital GRCE|Firefly Neuroscience, Inc - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Klotho Neurosciences Inc KLTO|neurosense-tx.com (NRSN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio RVPH|MTVA (MetaVia Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio NeurAxis Inc (NRXS)|Short-Term Debt to Equity Ratio HSDT (Helius Medical)|Short-Term Debt to Capital Coefficient passagebio.com|Short-Term Debt to Capital NEUP (Neuphoria Therapeutics)|NERV - Short-Term Debt to Equity Ratio|Athira - Short-Term Debt to Capital|ADXN - Short-Term Debt to Capital|alzamend.com (ALZN) - Short-Term Debt to Equity|Cyclerion Therapeutics, Inc. - Ratio of Short-Term Indebtedness to Capital|PTIX (Protagenic Therapeutics Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Pasithea|Short-Term Debt to Equity Cortigent, Inc. (CRGT)|Avenue Therapeutics Inc - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital BCLI (Brainstorm Cell)|chromocell.com (CHRO) - Current Liabilities to Capital|ELYM: Short-Term Debt to Equity Ratio|ITCI - Short-Term Debt to Capital|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Marinus Pharma - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Capital SAGE|Short-Term Debt to Equity Ratio Synaptogenix Inc. SNPX|Short-Term Debt to Capital TRVN (Trevena, Inc)|Short-Term Debt to Capital Vigil Neuroscience Inc. VIGL|WENA - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CERE (cerevel.com)